2 weeks Ago By ABMN Staff
Legal & General Group Plc reduced its stake in Dyne Therapeutics, Inc. ( NASDAQ:DYN – Free Report ) by 38.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 68,465 shares of the company’s stock after selling 43,192 shares during the quarter. Legal & General Group Plc’s holdings in Dyne Therapeutics were worth $1,613,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Other institutional investors and hedge funds have also bought and sold shares of the company.
Barclays PLC lifted its stake in Dyne Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 207,309 shares of the company’s stock worth $7,446,000 after purchasing an additional 128,246 shares during the last quarter.
JPMorgan Chase & Co. lifted its position in Dyne Therapeutics by 4.3% in the 3rd quarter.
JPMorgan Chase & Co. now owns 101,750 shares of the company’s stock worth $3,655,000 after buying an additional 4,236 shares during the last quarter. KBC Group NV boosted its stake in Dyne Therapeutics by 45.
3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after buying an additional 978 shares in the last quarter. China Universal Asset Management Co.
Ltd. grew its position in Dyne Therapeutics by 11.7% during the fourth quarter.
China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company’s stock valued at $508,000 after acquiring an additional 2,265 shares during the last quarter.
Finally, abrdn plc purchased a new position in shares of Dyne Therapeutics during the fourth quarter worth approximately $608,000. 96.68% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets A number of brokerages have recently issued reports on DYN. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research note on Monday, March 17th.
Piper Sandler cut their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research report on Friday, February 28th.
HC Wainwright reiterated a “buy” rating and issued a $46.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 17th. Royal Bank of Canada restated an “outperform” rating and set a $45.
00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company.
Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $47.46. Dyne Therapeutics Stock Down 0.
5 % Shares of DYN stock opened at $11.06 on Friday. The firm has a market capitalization of $1.
26 billion, a price-to-earnings ratio of -3.11 and a beta of 1.21.
The stock has a fifty day moving average of $10.79 and a 200 day moving average of $19.71.
Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $47.
45. Dyne Therapeutics ( NASDAQ:DYN – Get Free Report ) last posted its earnings results on Tuesday, March 4th. The company reported ($0.
88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04.
Equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.
Insiders Place Their Bets In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.
10. Following the completion of the transaction, the insider now owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65.
This trade represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link .
Insiders sold 6,237 shares of company stock worth $77,760 over the last three months. Company insiders own 20.77% of the company’s stock.
Dyne Therapeutics Profile ( Free Report ) Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Further Reading Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. ( NASDAQ:DYN – Free Report ). Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
